論文

• 57. Selective vascular disrupting therapy by lipid nanoparticle-mediated Fas ligand silencing and stimulation of STING.

  Endo R, Ueda T, Nagaoki T, Sato Y, Maishi N, Hida K, Harashima H*, Nakamura T*.
  Biomaterials 321: 123297 (2025).

  DOI : 10.1016/j.biomaterials.2025.123297.

  論文

• 56. Targeting tumor endothelial cells by EGCG using specific liposome delivery system inhibits vascular inflammation and thrombosis.

  Jia Z, Maishi N, Takekawa H, Matsuda A, Nakade T, Nakamura T, Harashima H, Hida Y, Hida K*.
  Cancer Medicine 13: e70462 (2024).

  DOI : 10.1002/cam4.70462

  論文

• 55. Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity.

  Endo R, Ueda T, Nagaoki T, Shima N, Sato Y, Harashima H*, Nakamura T*.
  J Control Release 372: 609-618 (2024).

  DOI : 10.1016/j.jconrel.2024.06.064

  論文

• 54. Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells.

  Khalifa AM, Nakamura T*, Sato Y, Harashima H*.
  Exp Hematol Oncol 13: 36 (2024).

  DOI : 10.1186/s40164-024-00502-w

  論文

• 53. Cancer immunotherapy with lipid nanoparticles loaded with a STING agonist against renal tumor lung metastasis.

  Nakamura T*, Sasaki S, Sato Y, Harashima H*.
  Pharmaceutics 16: 31 (2024).

  DOI : 10.3390/pharmaceutics16010031

  論文